Research programme: influenza A virus H7N9 combination vaccine - Replikins

Drug Profile

Research programme: influenza A virus H7N9 combination vaccine - Replikins

Alternative Names: Synthetic H7N9 pandemic influenza combination vaccine - Replikins

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Replikins
  • Class Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • No development reported Influenza A virus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Influenza-A-virus-infections(Prevention) in USA
  • 23 Apr 2013 Early research in Influenza A virus infections in USA (unspecified route)
  • 18 Apr 2013 Influenza A virus H7N9 combination vaccine - Replikins is available for licensing as of 18 Apr 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top